<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p192" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_192{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_192{left:306px;bottom:30px;}
#t3_192{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_192{left:346px;bottom:30px;}
#t5_192{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_192{left:517px;bottom:30px;}
#t7_192{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_192{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_192{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_192{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_192{left:35px;bottom:777px;letter-spacing:0.04px;word-spacing:0.39px;}
#tc_192{left:35px;bottom:754px;letter-spacing:0.09px;word-spacing:0.1px;}
#td_192{left:418px;bottom:761px;letter-spacing:-0.01px;}
#te_192{left:441px;bottom:754px;letter-spacing:0.07px;word-spacing:0.12px;}
#tf_192{left:35px;bottom:731px;letter-spacing:0.09px;word-spacing:0.1px;}
#tg_192{left:35px;bottom:707px;letter-spacing:0.09px;word-spacing:0.1px;}
#th_192{left:35px;bottom:684px;letter-spacing:0.31px;}
#ti_192{left:51px;bottom:692px;letter-spacing:-0.01px;}
#tj_192{left:70px;bottom:684px;word-spacing:0.19px;}
#tk_192{left:380px;bottom:692px;letter-spacing:0.1px;}
#tl_192{left:420px;bottom:684px;letter-spacing:0.04px;word-spacing:0.14px;}
#tm_192{left:35px;bottom:661px;letter-spacing:-0.1px;}
#tn_192{left:112px;bottom:668px;letter-spacing:0.1px;}
#to_192{left:153px;bottom:661px;letter-spacing:0.12px;word-spacing:0.06px;}
#tp_192{left:324px;bottom:668px;letter-spacing:0.1px;}
#tq_192{left:364px;bottom:661px;letter-spacing:0.08px;word-spacing:0.1px;}
#tr_192{left:35px;bottom:638px;letter-spacing:-0.16px;word-spacing:1.16px;}
#ts_192{left:208px;bottom:645px;}
#tt_192{left:254px;bottom:638px;letter-spacing:0.02px;word-spacing:0.47px;}
#tu_192{left:495px;bottom:645px;letter-spacing:-0.01px;}
#tv_192{left:518px;bottom:638px;letter-spacing:-0.37px;word-spacing:0.55px;}
#tw_192{left:35px;bottom:614px;letter-spacing:0.08px;word-spacing:0.11px;}
#tx_192{left:35px;bottom:591px;letter-spacing:-0.09px;}
#ty_192{left:104px;bottom:599px;letter-spacing:-0.01px;}
#tz_192{left:128px;bottom:591px;letter-spacing:0.01px;word-spacing:0.42px;}
#t10_192{left:35px;bottom:568px;letter-spacing:0.12px;word-spacing:0.2px;}
#t11_192{left:35px;bottom:545px;letter-spacing:0.06px;word-spacing:0.44px;}
#t12_192{left:35px;bottom:522px;letter-spacing:-0.08px;}
#t13_192{left:76px;bottom:529px;letter-spacing:0.1px;}
#t14_192{left:35px;bottom:482px;letter-spacing:0.13px;word-spacing:-0.44px;}
#t15_192{left:35px;bottom:459px;letter-spacing:0.05px;word-spacing:0.13px;}
#t16_192{left:35px;bottom:436px;letter-spacing:0.28px;word-spacing:-0.09px;}
#t17_192{left:172px;bottom:444px;letter-spacing:-0.01px;}
#t18_192{left:196px;bottom:436px;letter-spacing:-0.1px;word-spacing:0.29px;}
#t19_192{left:381px;bottom:444px;letter-spacing:0.1px;}
#t1a_192{left:35px;bottom:413px;letter-spacing:-0.05px;}
#t1b_192{left:207px;bottom:420px;letter-spacing:-0.01px;}
#t1c_192{left:232px;bottom:413px;letter-spacing:-0.09px;word-spacing:2.11px;}
#t1d_192{left:480px;bottom:413px;}
#t1e_192{left:490px;bottom:413px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t1f_192{left:35px;bottom:390px;letter-spacing:0.16px;word-spacing:0.02px;}
#t1g_192{left:110px;bottom:397px;letter-spacing:-0.01px;}
#t1h_192{left:133px;bottom:390px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1i_192{left:35px;bottom:366px;letter-spacing:0.04px;word-spacing:0.5px;}
#t1j_192{left:35px;bottom:343px;letter-spacing:0.04px;word-spacing:0.88px;}
#t1k_192{left:35px;bottom:320px;letter-spacing:-0.03px;word-spacing:0.83px;}
#t1l_192{left:257px;bottom:327px;letter-spacing:0.11px;}
#t1m_192{left:35px;bottom:281px;letter-spacing:-0.13px;word-spacing:0.56px;}
#t1n_192{left:35px;bottom:258px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1o_192{left:35px;bottom:234px;letter-spacing:0.11px;word-spacing:0.07px;}
#t1p_192{left:35px;bottom:211px;letter-spacing:0.06px;}
#t1q_192{left:35px;bottom:188px;letter-spacing:0.12px;word-spacing:0.06px;}
#t1r_192{left:35px;bottom:165px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1s_192{left:35px;bottom:141px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t1t_192{left:35px;bottom:118px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1u_192{left:35px;bottom:78px;letter-spacing:0.17px;word-spacing:-0.94px;}
#t1v_192{left:35px;bottom:55px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1w_192{left:618px;bottom:777px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1x_192{left:618px;bottom:754px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1y_192{left:618px;bottom:731px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1z_192{left:618px;bottom:707px;letter-spacing:0.16px;word-spacing:0.03px;}
#t20_192{left:618px;bottom:684px;letter-spacing:-0.01px;word-spacing:0.2px;}
#t21_192{left:732px;bottom:692px;letter-spacing:-0.01px;}
#t22_192{left:750px;bottom:684px;letter-spacing:0.11px;word-spacing:0.08px;}
#t23_192{left:618px;bottom:661px;letter-spacing:0.05px;word-spacing:-1.1px;}
#t24_192{left:618px;bottom:638px;letter-spacing:0.06px;word-spacing:0.12px;}
#t25_192{left:618px;bottom:614px;letter-spacing:0.04px;}
#t26_192{left:618px;bottom:575px;letter-spacing:0.15px;word-spacing:0.03px;}
#t27_192{left:618px;bottom:552px;letter-spacing:0.15px;word-spacing:0.04px;}
#t28_192{left:618px;bottom:529px;letter-spacing:0.15px;word-spacing:0.04px;}
#t29_192{left:618px;bottom:506px;letter-spacing:0.15px;word-spacing:0.03px;}
#t2a_192{left:618px;bottom:482px;letter-spacing:0.07px;word-spacing:0.12px;}
#t2b_192{left:618px;bottom:459px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2c_192{left:618px;bottom:436px;letter-spacing:0.13px;word-spacing:0.05px;}
#t2d_192{left:618px;bottom:413px;letter-spacing:0.09px;word-spacing:-0.83px;}
#t2e_192{left:618px;bottom:390px;letter-spacing:0.04px;word-spacing:0.15px;}
#t2f_192{left:618px;bottom:366px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2g_192{left:618px;bottom:343px;letter-spacing:0.05px;word-spacing:0.13px;}
#t2h_192{left:618px;bottom:320px;letter-spacing:0.02px;word-spacing:0.17px;}
#t2i_192{left:618px;bottom:297px;letter-spacing:0.12px;word-spacing:-0.07px;}
#t2j_192{left:618px;bottom:273px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2k_192{left:618px;bottom:250px;letter-spacing:0.18px;word-spacing:-0.17px;}
#t2l_192{left:1010px;bottom:250px;letter-spacing:0.16px;word-spacing:0.04px;}
#t2m_192{left:618px;bottom:227px;letter-spacing:0.19px;}
#t2n_192{left:1018px;bottom:227px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2o_192{left:618px;bottom:204px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2p_192{left:618px;bottom:162px;letter-spacing:0.19px;}
#t2q_192{left:618px;bottom:138px;letter-spacing:0.08px;word-spacing:0.37px;}
#t2r_192{left:618px;bottom:116px;letter-spacing:0.17px;word-spacing:0.02px;}
#t2s_192{left:618px;bottom:93px;letter-spacing:0.06px;word-spacing:0.12px;}
#t2t_192{left:988px;bottom:93px;}
#t2u_192{left:1005px;bottom:93px;letter-spacing:0.14px;word-spacing:0.04px;}
#t2v_192{left:618px;bottom:69px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2w_192{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_192{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_192{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_192{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_192{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_192{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_192{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_192{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s7_192{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s8_192{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s9_192{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts192" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg192Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg192" style="-webkit-user-select: none;"><object width="1210" height="935" data="192/192.svg" type="image/svg+xml" id="pdf192" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_192" class="t s0_192">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_192" class="t s1_192">© </span>
<span id="t3_192" class="t s0_192">(NCCN </span>
<span id="t4_192" class="t s1_192">© </span>
<span id="t5_192" class="t s0_192">), All rights reserved. NCCN Guidelines </span>
<span id="t6_192" class="t s1_192">® </span>
<span id="t7_192" class="t s0_192">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_192" class="t s2_192">NCCN Guidelines Version 4.2024 </span>
<span id="t9_192" class="t s2_192">Head and Neck Cancers </span>
<span id="ta_192" class="t s3_192">MS-51 </span>
<span id="tb_192" class="t s4_192">may be particularly suitable in patients with a PS of 0 or 1 and either a </span>
<span id="tc_192" class="t s4_192">large burden of disease or nearing a clinical crisis. </span>
<span id="td_192" class="t s5_192">636 </span>
<span id="te_192" class="t s4_192">Other combination </span>
<span id="tf_192" class="t s4_192">regimens recommended by the panel for treatment of metastatic SCCHN </span>
<span id="tg_192" class="t s4_192">include: 1) cisplatin or carboplatin, plus 5-FU with cetuximab (category </span>
<span id="th_192" class="t s4_192">1) </span>
<span id="ti_192" class="t s5_192">635 </span>
<span id="tj_192" class="t s4_192">; 2) cisplatin or carboplatin, plus a taxane </span>
<span id="tk_192" class="t s5_192">536,537 </span>
<span id="tl_192" class="t s4_192">; 3) cisplatin with </span>
<span id="tm_192" class="t s4_192">cetuximab </span>
<span id="tn_192" class="t s5_192">542,640 </span>
<span id="to_192" class="t s4_192">; 4) cisplatin with 5-FU </span>
<span id="tp_192" class="t s5_192">537,538 </span>
<span id="tq_192" class="t s4_192">; or 5) cetuximab with a </span>
<span id="tr_192" class="t s4_192">platinum and a taxane. </span>
<span id="ts_192" class="t s5_192">640-644 </span>
<span id="tt_192" class="t s4_192">Extrapolating from Guigay et al, </span>
<span id="tu_192" class="t s5_192">644 </span>
<span id="tv_192" class="t s4_192">a taxane </span>
<span id="tw_192" class="t s4_192">can be considered, when used in combination with pembrolizumab and a </span>
<span id="tx_192" class="t s4_192">platinum. </span>
<span id="ty_192" class="t s5_192">636 </span>
<span id="tz_192" class="t s4_192">Cetuximab combined with an anti–PD-1 antibody </span>
<span id="t10_192" class="t s4_192">(pembrolizumab or nivolumab) is also an option for recurrent or </span>
<span id="t11_192" class="t s4_192">metastatic SCCHN based on results from non-randomized phase II </span>
<span id="t12_192" class="t s4_192">trials. </span>
<span id="t13_192" class="t s5_192">645,646 </span>
<span id="t14_192" class="t s4_192">Other options that the panel considers useful in certain circumstances for </span>
<span id="t15_192" class="t s4_192">patients with recurrent or metastatic SCCHN are cisplatin/pemetrexed </span>
<span id="t16_192" class="t s4_192">(for PS 0–1 only), </span>
<span id="t17_192" class="t s5_192">647 </span>
<span id="t18_192" class="t s4_192">cetuximab with a taxane, </span>
<span id="t19_192" class="t s5_192">640,644 </span>
<span id="t1a_192" class="t s4_192">gemcitabine/paclitaxel, </span>
<span id="t1b_192" class="t s5_192">648 </span>
<span id="t1c_192" class="t s4_192">and nivolumab/ipilimumab (CPS </span><span id="t1d_192" class="t s6_192">≥</span><span id="t1e_192" class="t s4_192">20 and first- </span>
<span id="t1f_192" class="t s4_192">line only). </span>
<span id="t1g_192" class="t s5_192">649 </span>
<span id="t1h_192" class="t s4_192">These are all category 2B options except for </span>
<span id="t1i_192" class="t s4_192">paclitaxel/cetuximab. Single agents recommended by the panel include </span>
<span id="t1j_192" class="t s4_192">cisplatin, carboplatin, paclitaxel, docetaxel, 5-FU, methotrexate, </span>
<span id="t1k_192" class="t s4_192">capecitabine, and cetuximab. </span>
<span id="t1l_192" class="t s5_192">538,541-549,551,552,650,651 </span>
<span id="t1m_192" class="t s7_192">Locoregionally Recurrent or Persistent Disease </span>
<span id="t1n_192" class="t s4_192">A multidisciplinary evaluation is critical in defining appropriate therapy for </span>
<span id="t1o_192" class="t s4_192">patients with local and/or regional disease recurrence or persistence </span>
<span id="t1p_192" class="t s4_192">without distant metastasis. A subset of these patients can be approached </span>
<span id="t1q_192" class="t s4_192">with curative intent local therapy, and the therapeutic options depend on </span>
<span id="t1r_192" class="t s4_192">several factors, including: type of prior therapy (surgery vs. radiation), </span>
<span id="t1s_192" class="t s4_192">interval between prior therapy and recurrence, desire for functional </span>
<span id="t1t_192" class="t s4_192">preservation, and patient PS. </span>
<span id="t1u_192" class="t s4_192">In general, surgery is recommended for resectable recurrent or persistent </span>
<span id="t1v_192" class="t s4_192">locoregional disease, in the absence of distant metastatic disease; </span>
<span id="t1w_192" class="t s4_192">adjuvant therapy depends on pathologic risk factors. Patients with </span>
<span id="t1x_192" class="t s4_192">resectable recurrent or persistent locoregional disease who have not </span>
<span id="t1y_192" class="t s4_192">previously been treated with RT may also be treated with concurrent </span>
<span id="t1z_192" class="t s4_192">systemic therapy/RT (high-dose cisplatin is the preferred [category 1] </span>
<span id="t20_192" class="t s4_192">systemic agent </span>
<span id="t21_192" class="t s5_192">264 </span>
<span id="t22_192" class="t s4_192">). Combination systemic therapy followed by RT or </span>
<span id="t23_192" class="t s4_192">systemic therapy/RT (category 2B) may be considered for cytoreduction or </span>
<span id="t24_192" class="t s4_192">symptom control, followed by local therapy such as surgery as clinically </span>
<span id="t25_192" class="t s4_192">indicated. </span>
<span id="t26_192" class="t s4_192">Among patients with unresectable recurrence or persistence in a </span>
<span id="t27_192" class="t s4_192">previously non-irradiated field, RT with concurrent systemic therapy is </span>
<span id="t28_192" class="t s4_192">recommended, with the duration of RT and choice of systemic agent </span>
<span id="t29_192" class="t s4_192">dependent on the PS. No randomized data exist that define a preferred </span>
<span id="t2a_192" class="t s4_192">systemic therapy/RT combination in this setting, although early-phase </span>
<span id="t2b_192" class="t s4_192">studies have explored carboplatin, PD-1 inhibitors, and cetuximab. In </span>
<span id="t2c_192" class="t s4_192">situations where patient or tumor factors render patients as poor </span>
<span id="t2d_192" class="t s4_192">candidates for curative-intent radiation or surgery, the treatment approach </span>
<span id="t2e_192" class="t s4_192">is the same as that for patients with metastatic disease; however, in the </span>
<span id="t2f_192" class="t s4_192">absence of distant metastatic disease and/or in the presence of </span>
<span id="t2g_192" class="t s4_192">symptoms, re-irradiation with systemic therapy is increasingly feasible </span>
<span id="t2h_192" class="t s4_192">(see below). Locoregional treatment such as palliative radiation may be </span>
<span id="t2i_192" class="t s4_192">considered in the presence of distant metastasis with locoregional failure </span>
<span id="t2j_192" class="t s4_192">to alleviate tumor burden-related symptoms. RT fractionation for patients </span>
<span id="t2k_192" class="t s4_192">with recurrent or persistent disease is described in </span><span id="t2l_192" class="t s8_192">Very Advanced Head </span>
<span id="t2m_192" class="t s8_192">and Neck Cancers: Principles of Radiation Therapy </span><span id="t2n_192" class="t s4_192">in the NCCN </span>
<span id="t2o_192" class="t s4_192">Guidelines for Head and Neck Cancers). </span>
<span id="t2p_192" class="t s8_192">Reirradiation </span>
<span id="t2q_192" class="t s4_192">Reirradiation may be offered to patients with locally and/or regionally </span>
<span id="t2r_192" class="t s4_192">recurrent or persistent H&amp;N cancer, using IMRT, PBT, or SBRT. A </span>
<span id="t2s_192" class="t s4_192">randomized phase III multicenter trial in France (</span><span id="t2t_192" class="t s8_192">N </span><span id="t2u_192" class="t s4_192">= 130) showed that </span>
<span id="t2v_192" class="t s4_192">reirradiation combined with systemic therapy in patients following a </span>
<span id="t2w_192" class="t s9_192">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
